BeiGene Terminates its Worldwide Development and Commercialization Agreement with Celgene for Tislelizumab
Shots:
- BeiGene to receive $150M and regains WW rights for tislelizumab with their mutual termination of WW development & commercialization agreement with Celgene- following the pending acquisition of Celgene by BMS
- In Jul’17- BeiGene granted exclusive WW rights (Ex- Asia) of tislelizumab for solid tumor and retained global rights for hematology & solid tumor in Asia. Additionally- BeiGene got exclusive commercialization rights for Celgene’s Abraxane- Revlimid- Vidaza in China which is unaffected with the termination deal of tislelizumab
- Tislelizumab (BGB-A317) is an anti-PD-1 antibody- targeting IgG4- minimizing the binding of FcγR on macrophages. NMPA has accepted its NDA for tislelizumab in patients with R/R cHL & LA or metastatic UC and has received PR for R/R cHL filing
Ref: BeiGene | Image: Chemistry World
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com